Search results
ASLAN expands research on atopic dermatitis treatment By Investing.com
Investing.com· 5 days agoASLAN Pharmaceuticals (NASDAQ:ASLN), a clinical-stage biopharmaceutical company, has announced a new...
Review Addresses Skin Manifestations of Cystic Fibrosis
Medscape· 1 day agoA review covers the various skin manifestations seen in patients with CF, which include those...
Incyte's (INCY) Q1 Earnings & Revenues Fall Shy of Estimates
Zacks via Yahoo Finance· 7 days agoOpzelura cream 1.5% is approved for the topical treatment of non-segmental vitiligo in adult and...
Nektar to Announce Financial Results for the First Quarter 2024 on Thursday, May 9, 2024, After...
The Grass Valley Union· 4 days agoNektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the first quarter 2024 on Thursday, May 9, 2024, after the close of U.S.-based financial markets. Howard Robin, President ...
Kymera (KYMR) Q1 Loss Narrower Than Expected, Pipeline in Focus
Zacks via Yahoo Finance· 4 days agoKymera (KYMR) reports a narrower-than-expected loss in the first quarter. The company expects the...
Regeneron’s stock rallies as pipeline prospects outweigh earnings miss
Market Watch· 5 days agoThe revenue shortfall was partly due to a decline in sales of the company’s blockbuster eye drug...
Gene expression analyses identify potential drivers of chronic allergic inflammation
Medical Xpress· 6 days agoCurrently, most therapies for allergic diseases require lifelong treatment. Allergic reactions, characterized by ongoing (type 2) inflammation in response to chronic antigen ...
Incyte misses quarterly profit on weak sales of lead drug
Reuters· 7 days ago, opens new tab on Tuesday reported first-quarter profit below Wall Street estimates on weak sales of its blood cancer drug Jakafi, sending its shares down 2.4%. The company is working on strengthening ...
Incyte shares dip after earnings, guidance miss By Investing.com
Investing.com· 7 days agoIncyte (NASDAQ:INCY) Corporation (NASDAQ:INCY), a global biopharmaceutical company, reported...
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 4 days agoKymera Therapeutics, Inc. (NASDAQ:KYMR) Q1 2024 Earnings Call Transcript May 3, 2024 Kymera...